A whole-food, plant-based randomized controlled trial in metastatic breast cancer: weight, cardiometabolic, and hormonal outcomes
Breast Cancer Research and Treatment · 2024
DOI: 10.1007/s10549-024-07266-1 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Breast Cancer Research and Treatment, 2024. Verfasst von Thomas M Campbell und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Family Medicine, University of Rochester Medical Center, 777 South Clinton Ave, Rochester, NY, 14620, USA. Thomas_campbell@urmc.rochest…. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, US National Institutes of Health, Highland Hospital Foundation.
Abstract (Originalsprache)
Purpose
Breast cancer treatment is associated with weight gain, and obesity and its related cardiometabolic and hormonal risk factors have been associated with poorer outcomes. Dietary intervention may address these risk factors, but limited research has been done in the setting of metastatic breast cancer requiring systemic therapy.
Methods
Women with metastatic breast cancer on stable treatment were randomized 2:1 to an 8-week intervention ( n = 21) or control ( n = 11). The intervention included weekly assessment visits and an ad libitum whole-food, plant-based (WFPB) diet with provided meals. Cardiometabolic, hormonal, and cancer markers were assessed at baseline, 4 weeks, and 8 weeks.
Results
Within the intervention group, mean weight decreased by 6.6% ( p < 0.01) after 8 weeks. Fasting insulin decreased from 16.8 uIU/L to 11.2 uIU/L ( p < 0.01), concurrent with significantly reduced insulin resistance. Total cholesterol decreased from 193.6 mg/dL to 159 mg/dL ( p < 0.01), and low-density lipoprotein (LDL) cholesterol decreased from 104.6 mg/dL to 82.2 mg/dL ( p < 0.01). Total testosterone was unchanged, but free testosterone trended lower within the intervention group ( p = 0.08) as sex hormone binding globulin increased from 74.3 nmol/L to 98.2 nmol/L ( p < 0.01). There were no significant differences in cancer progression markers at week 8, although mean CA 15-3, CA 27.29, and CEA were lower in the intervention group ( p = 0.53, p = 0.23, and p = 0.54, respectively) compared to control, when adjusted for baseline.
Conclusion
WFPB dietary changes during treatment for metastatic breast cancer are well tolerated and significantly improve weight, cardiometabolic and hormonal parameters. Longer studies are warranted to assess the durability of changes.
Trial registration
First registered at Clinicaltrials.gov (NCT03045289) on February 7, 2017.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Family Medicine, University of Rochester Medical Center, 777 South Clinton Ave, Rochester, NY, 14620, USA. Thomas_campbell@urmc.rochester.edu.
- Department of Public Health Sciences, University of Rochester Medical Center, Rochester, NY, USA.
- Department of Surgery, Cancer Control, University of Rochester Medical Center, Rochester, NY, USA.
- Department of Family Medicine, University of Rochester Medical Center, 777 South Clinton Ave, Rochester, NY, 14620, USA.
- Clinical Research Center, University of Rochester Medical Center, Rochester, NY, USA.
- Memorial Sloan Kettering Cancer Center, Westchester, NY, USA.
Förderung
- NCI NIH HHS
- US National Institutes of Health
- Highland Hospital Foundation
Zitieren
APA
Campbell, T. M., Campbell, E. K., Culakova, E., Blanchard, L. M., Wixom, N., Guido, J. J., Fetten, J., Huston, A., Shayne, M., Janelsins, M. C., Mustian, K. M., Moore, R. G., & Peppone, L. J. (2024). A whole-food, plant-based randomized controlled trial in metastatic breast cancer: weight, cardiometabolic, and hormonal outcomes. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07266-1
Vancouver
Campbell TM, Campbell EK, Culakova E, Blanchard LM, Wixom N, Guido JJ, et al. A whole-food, plant-based randomized controlled trial in metastatic breast cancer: weight, cardiometabolic, and hormonal outcomes. Breast Cancer Research and Treatment. 2024. doi:10.1007/s10549-024-07266-1
BibTeX
@article{Campbell2024,
author = {Campbell, Thomas M and Campbell, Erin K and Culakova, Eva and Blanchard, Lisa M and Wixom, Nellie and Guido, Joseph J and Fetten, James and Huston, Alissa and Shayne, Michelle and Janelsins, Michelle C and Mustian, Karen M and Moore, Richard G and Peppone, Luke J},
title = {A whole-food, plant-based randomized controlled trial in metastatic breast cancer: weight, cardiometabolic, and hormonal outcomes},
journal = {Breast Cancer Research and Treatment},
year = {2024},
doi = {10.1007/s10549-024-07266-1}
}
EUVIMED